Pathogenesis of familial Parkinson's disease: New insights based on monogenic forms of Parkinson's disease

Journal of Neurochemistry

Volumn 111, Issue 5, 2009, Pages 1075-1093

  Hatano, Takun ^a   Kubo, Shin Ichiro ^a   Sato, Shigeto ^a   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Autophagy; Familial Parkinson's disease; Membrane trafficking system; Mitochondria; Oxidative stress; Ubiquitin proteasome system

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE 13A2; ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

AUTOPHAGY; CELL FUNCTION; CLINICAL FEATURE; DOMINANT INHERITANCE; FAMILIAL DISEASE; GENE INTERACTION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; INHERITANCE; MEMBRANE TRANSPORT; MITOCHONDRION; MOLECULAR MECHANICS; MONOGENIC DISORDER; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RECESSIVE INHERITANCE; REVIEW;

ANIMALS; AUTOPHAGY; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYSOSOMES; MITOCHONDRIA; PARKINSON DISEASE; UBIQUITIN;

EID: 70350759686     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06403.x     Document Type: Review

References (271)

1. Abbas N., Lucking C. B., Ricard S. et al. (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet. 8, 567 574.
2. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239 252.
3. Abou-Sleiman P. M., Healy D. G., Quinn N., Lees A. J. Wood N. W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283 286.
4. Abou-Sleiman P. M., Muqit M. M., McDonald N. Q. et al. (2006) A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann. Neurol. 60, 414 419.
5. Ahn T. B., Kim S. Y., Kim J. Y. et al. (2008) alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70, 43 49.
6. Alegre-Abarrategui J., Ansorge O., Esiri M. Wade-Martins R. (2008) LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34, 272 283.
7. Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H. Kawai M. (1998) Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93 100.
8. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's desease. Science 295, 865 868.
9. Bandopadhyay R., Kingsbury A. E., Cookson M. R. et al. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127, 420 430.
10. Beilina A., Van Der Brug M., Ahmad R., Kesavapany S., Miller D. W., Petsko G. A. Cookson M. R. (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. USA 102, 5703 5708.
11. Berg D., Schweitzer K., Leitner P. et al. (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 128, 3000 3011.
12. Biskup S., Moore D. J., Celsi F. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557 569.
13. Blackinton J. G., Anvret A., Beilina A., Olson L., Cookson M. R. Galter D. (2007) Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res. 1184, 10 16.
14. Bonifati V., Breedveld G. J., Squitieri F. et al. (2002) Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann. Neurol. 51, 253 256.
15. Bonifati V., Rizzu P., van Baren M. J. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256 259. (Pubitemid 36131051)
16. Bonifati V., Rohe C. F., Breedveld G. J. et al. (2005) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65, 87 95.
17. Bossy-Wetzel E., Schwarzenbacher R. Lipton S. A. (2004) Molecular pathways to neurodegeneration. Nat. Med., 10 (Suppl S2 S9.
18. Bras J., Simon-Sanchez J., Federoff M., Morgadinho A., Januario C., Ribeiro M., Cunha L., Oliveira C. Singleton A. B. (2009) Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum. Mol. Genet. 18, 341 346.
19. Brown D. A. London E. (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14, 111 136.
20. van der Brug M. P., Blackinton J., Chandran J. et al. (2008) RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathway. Proc. Natl Acad. Sci. USA 105, 10244 10249.
21. Canet-Aviles R. M., Wilson M. A., Miller D. W. et al. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 101, 9103 9108.
22. Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167 1169.
23. Chaudhuri K. R., Healy D. G. Schapira A. H. (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5, 235 245.
24. Choi P., Snyder H., Petrucelli L. et al. (2003) SEPT5-v2 is a parkin-binding protein. Brain Res. Mol. Brain Res. 117, 179 189.
25. Chung K. K., Zhang Y., Lim K. L., Tanaka Y., Huang H., Gao J., Ross C. A., Dawson V. L. Dawson T. M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144 1150.
26. Chung K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L. Dawson T. M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328 1331.
27. Clark L. N., Afridi S., Mejia-Santana H. et al. (2004) Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. Mov. Disord. 19, 796 800.
28. Clark I. E., Dodson M. W., Jiang C., Cao J. H., Huh J. R., Seol J. H., Yoo S. J., Hay B. A. Guo M. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162 1166.
29. Clements C. M., McNally R. S., Conti B. J., Mak T. W. Ting J. P. (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant trascriptional master regulator Nrf2. Proc. Natl. Acad. Sci. USA 103, 15091 15096.
30. Conway K. A., Harper J. D. Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318 1320.
31. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. Lansbury P. T. Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571 576.
32. Cookson M. R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29 52.
33. Cookson M. R., Xiromerisiou G. Singleton A. (2005) How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Curr. Opin. Neurol. 18, 706 711.
34. Cookson M. R., Dauer W., Dawson T., Fon E. A., Guo M. Shen J. (2007) The roles of kinases in familial Parkinson's disease. J. Neurosci. 27, 11865 11868.
35. Cooper A. A., Gitler A. D., Cashikar A. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324 328.
36. Corti O., Hampe C., Houtnikova H. et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12, 1427 1473.
37. Covy J. P., Yuan W., Waxman E. A., Hurtig H. I., Van Deerlin V. M. Giasson B. I. (2009) Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov. Disord. 24, 32 39.
38. Crowther R. A., Daniel S. E. Goedert M. (2000) Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292, 128 130.
39. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292 1295.
40. Dachsel J. C., Taylor J. P., Mok S. S. et al. (2007) Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 13, 382 385.
41. Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99, 14524 14529.
42. Dekker M., Bonifati V., van Swieten J. et al. (2003) Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord. 18, 751 757.
43. Deng H., Dodson M. W., Huang H. Guo M. (2008) The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl Acad. Sci. USA 105, 14503 14508.
44. Di Fonzo A., Wu-Chou Y. H., Lu C. S. et al. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7, 133 138.
45. Di Fonzo A., Chien H. F., Socal M. et al. (2007) ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68, 1557 1562.
46. Djarmati A., Hedrich K., Svetel M. et al. (2004) Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: parkin mutation frequency depends on ethnic origin of patients. Hum. Mutat. 23, 525.
47. Djarmati A., Hedrich K., Svetel M., Lohnau T., Schwinger E., Romac S., Pramstaller P. P., Kostic V. Klein C. (2006) Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease? Mov. Disord. 21, 1526 1530.
48. Fallon L., Belanger C. M., Corera A. T. et al. (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 8, 834 842.
49. Farrer M., Chan P., Chen R. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50, 293 300.
50. Feany M. B. Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394 398.
51. Fleming S. M., Fernagut P. O. Chesselet M. F. (2005) Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2, 495 503.
52. Fortin D. L., Troyer M. D., Nakamura K., Kubo S. I., Anthony M. D. Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 6715 6723.
53. Freichel C., Neumann M., Ballard T. et al. (2007) Age-dependent cognitive dcline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 28, 1421 1435.
54. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. Iwatsubo T. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160 164.
55. Fukae J., Sato S., Shiba K., Sato K., Mori H., Sharp P. A., Mizuno Y. Hattori N. (2009) Programmed cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease. FEBS Lett. 583, 521 525.
56. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S. Obata F. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296 301.
57. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S. Obata F. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918 921.
58. Funayama M., Li Y., Tomiyama H. et al. (2007) Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18, 273 275.
59. Funayama M., Li Y., Tsoi T. H. et al. (2008) Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov. Disord. 23, 1461 1465.
60. Gai W. P., Pountney D. L., Power J. H., Li Q. X., Culvenor J. G., McLean C. A., Jensen P. H. Blumbergs P. C. (2003) alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp. Neurol. 181, 68 78.
61. Gandhi S., Muqit M. M., Stanyer L. et al. (2006) PINK1 protein in normal human brain and Parkinson's disease. Brain 129, 1720 1731.
62. Gandhi P. N., Wang X., Zhu X., Chen S. G. Wilson-Delfosse A. L. (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86, 1711 1720.
63. Gautier C. A., Kitada T. Shen J. (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl Acad. Sci. USA 105, 11364 11369.
64. George J. M., Jin H., Woods W. S. Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the Zebra Finch. Neuron 15, 361 372.
65. Giasson B. I., Uryu K., Trojanowski J. Q. Lee V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619 7622.
66. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985 989.
67. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521 533.
68. Giasson B. I., Covy J. P., Bonini N. M., Hurtig H. I., Farrer M. J., Trojanowski J. Q. Van Deerlin V. M. (2006) Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315 322.
69. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C. Cicchetti F. (2009) Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions. J. Neurochem. 109, 1469 1482.
70. Gilks W. P., Abou-Sleiman P. M., Gandhi S. et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415 416.
71. Giordana M. T., D'Agostino C., Albani G., Mauro A., Di Fonzo A., Antonini A. Bonifati V. (2007) Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov. Disord. 22, 275 278. (Pubitemid 46374779)
72. Gitler A. D., Chesi A., Geddie M. L. et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308 315.
73. Glaser C. B., Yamin G., Uversky V. N. Fink A. L. (2005) Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim. Biophys. Acta 1703, 157 169.
74. Gloeckner C. J., Kinkl N., Schumacher A., Braun R. J., O'Neill E., Meitinger T., Kolch W., Prokisch H. Ueffing M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223 232.
75. Goldberg M. S., Fleming S. M., Palacino J. J. et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628 43635.
76. Goldberg M. S., Pisani A., Haburcak M. et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45, 489 496.
77. Gouider-Khouja N., Larnaout A., Amouri R. et al. (2003) Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism Relat Disord 9, 247 251.
78. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. Giasson B. I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800 7807.
79. Greene J. C., Whitworth A. J., Kuo I., Andrews L. A., Feany M. B. Pallanck L. J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078 4083.
80. Greggio E., Jain S., Kingsbury A. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329 341.
81. Guo J. T., Chen A. Q., Kong Q., Zhu H., Ma C. M. Qin C. (2008) Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell. Mol. Neurobiol. 28, 35 47.
82. Hague S., Rogaeva E., Hernandez D. et al. (2003) Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol. 54, 271 274.
83. Haque M. E., Thomas K. J., D'Souza C. et al. (2008) Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl Acad. Sci. USA 105, 1716 1721.
84. Harhangi B. S., Farrer M. J., Lincoln S. et al. (1999) The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 270, 1 4.
85. Hasegawa K., Stoessl A. J., Yokoyama T., Kowa H., Wszolek Z. K. Yagishita S. (2008a) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15, 300 306.
86. Hasegawa T., Treis A., Patenge N., Fiesel F. C., Springer W. Kahle P. J. (2008b) Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem. 105, 1700 1715.
87. Hatano Y., Li Y., Sato K. et al. (2004a) Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56, 424 427.
88. Hatano Y., Sato K., Elibol B. et al. (2004b) PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 63, 1482 1485.
89. Hatano T., Kubo S. I., Imai S., Maeda M., Ishikawa K., Mizuno Y. Hattori N. (2007) Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 16, 678 690.
90. Hattori N. Mizuno Y. (2004) Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364, 722 724.
91. Hayashi S., Wakabayashi K., Ishikawa A. et al. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord. 15, 884 888.
92. Hedrich K., Djarmati A., Schafer N. et al. (2004) DJ-1 (PARK7) mutations are less frequent than parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62, 389 394.
93. Hedrich K., Hagenah J., Djarmati A. et al. (2006) Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch. Neurol. 63, 833 838.
94. Hering R., Strauss K. M., Tao X. et al. (2004) Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum. Mutat. 24, 321 329.
95. Higashi S., Biskup S., West A. B. et al. (2007a) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 1155, 208 219. (Pubitemid 46900930)
96. Higashi S., Moore D. J., Colebrooke R. E., Biskup S., Dawson V. L., Arai H., Dawson T. M. Emson P. C. (2007b) Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 100, 368 381.
97. Ho C. C.-Y., Rideout H. J., Ribe E., Troy C. M. Dauer W. T. (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 29, 1011 1016.
98. Huynh D. P., Scoles D. R., Nguyen D. Pulst S. M. (2003) The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 12, 2587 2597.
99. Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M. T. Barone P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16, 1319 1326.
100. Ibanez P., Bonnet A. M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A. Brice A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169 1171.
101. Ihara M., Yamasaki N., Hagiwara A. et al. (2007) Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53, 519 533.
102. Ikeuchi T., Kakita A., Shiga A. et al. (2008) Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 65, 514 519.
103. Imai Y., Soda M. Takahashi R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661 35664.
104. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105, 891 902.
105. Inden M., Taira T., Kitamura Y. et al. (2006) PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis 24, 144 158.
106. Ischiropoulos H. Beckman J. S. (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111, 163 169.
107. Itier J. M., Ibanez P., Mena M. A. et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12, 2277 2291.
108. Ito G., Okai T., Fujino G., Takeda K., Ichijo H., Katada T. Iwatsubo T. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380 1388.
109. Jaleel M., Nichols R. J., Deak M., Campbell D. G., Gillardon F., Knebel A. Alessi D. R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307 317.
110. Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292 26294.
111. Jiang H., Ren Y., Zhao J. Feng J. (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13, 1745 1754.
112. Jones J. M., Datta P., Srinivasula S. M. et al. (2003) Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 425, 721 727.
113. Khan N. L., Jain S., Lynch J. M. et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128, 2786 2796.
114. Kim R. H., Peters M., Jang Y. et al. (2005a) DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263 273.
115. Kim R. H., Smith P. D., Aleyasin H. et al. (2005b) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102, 5215 5220.
116. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605 608. (Pubitemid 28207717)
117. Kitada T., Pisani A., Porter D. R. et al. (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl Acad. Sci. USA 104, 11441 11446.
118. Klein C. Schlossmacher M. G. (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69, 2093 2104.
119. Klein C., Pramstaller P. P., Kis B. et al. (2000) Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol. 48, 65 71.
120. Ko H. S., von Coelln R., Sriram S. R. et al. (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968 7978.
121. Kruger R., Kuhn W., Muller T. et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106 108.
122. Kubo S. I., Kitami T., Noda S. et al. (2001) Parkin is associated with cellular vesicles. J. Neurochem. 78, 42 54.
123. Kubo S. I., Nemani V. M., Chalkley R. J., Anthony M. D., Hattori N., Mizuno Y., Edwards R. H. Fortin D. L. (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J. Biol. Chem. 280, 31664 31672.
124. Kubo S. I., Hattori N. Mizuno Y. (2006) Recessive Parkinson's disease. Mov. Disord. 21, 885 893.
125. Kumazawa R., Tomiyama H., Li Y. et al. (2008) Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. Arch. Neurol. 65, 802 808.
126. Kuwahara T., Koyama A., Gengyo-Ando K., Masuda M., Kowa H., Tsunoda M., Mitani S. Iwatsubo T. (2006) Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281, 334 340.
127. Lakso M., Vartiainen S., Moilanen A. M., Sirvio J., Thomas J. H., Nass R., Blakely R. D. Wong G. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86, 165 172.
128. Larsen C. N., Price J. S. Wilkinson K. D. (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35, 6735 6744.
129. Larsen C. N., Krantz B. A. Wilkinson K. D. (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37, 3358 3368.
130. Larsen K. E., Schmitz Y., Troyer M. D. et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26, 11915 11922.
131. de Lau L. M. Breteler M. M. (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5, 525 535.
132. Lautier C., Goldwurm S., Durr A., Giovannone B., Tsiaras W. G., Pezzoli G., Brice A. Smith R. J. (2008) Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am. J. Hum. Genet. 82, 822 833.
133. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G. Selkoe D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 11, 1214 1221.
134. Lee V. M. Trojanowski J. Q. (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33 38.
135. Leroy E., Boyer R., Auburger G. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451 452.
136. Lesage S. Brice A. (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48 R59.
137. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A. L., Janin S., Pollak P. Brice A. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422 423.
138. Li W., Hoffman P. N., Stirling W., Price D. L. Lee M. K. (2004) Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J. Neurochem. 88, 401 410.
139. Lim K. L., Chew K. C., Tan J. M. et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25, 2002 2009.
140. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., Lynch T., Hardy J. Farrer M. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10, 427 429. (Pubitemid 29104826)
141. Liu Y., Fallon L., Lashuel H. A., Liu Z. Lansbury P. T. Jr. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209 218.
142. Liu Z., Wang X., Yu Y. et al. (2008) A Drosophila model of LRRK2-linked parkinsonism. Proc. Natl Acad. Sci. USA 105, 2693 2698.
143. Lo Bianco C., Schneider B. L., Bauer M., Sajadi A., Brice A., Iwatsubo T. Aebischer P. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 17510 17515.
144. Lowe J., McDermott H., Landon M., Mayer R. J. Wilkinson K. D. (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161, 153 160.
145. Lu Y. W. Tan E. K. (2008) Molecular biology changes associated with LRRK2 mutations in Parkinson's disease. J. Neurosci. Res. 86, 1895 1901.
146. Machida Y., Chiba T., Takayanagi A. et al. (2005) Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem. Biophys. Res. Commun. 332, 233 240.
147. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K. Abeliovich A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587 593.
148. Maraganore D. M., Farrer M. J., Hardy J. A., Lincoln S. J., McDonnell S. K. Rocca W. A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53, 1858 1860.
149. Maraganore D. M., de Andrade M., Elbaz A. et al. (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661 670.
150. Marin I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23, 2423 2433.
151. Marin I., van Egmond W. N. van Haastert P. J. (2008) The Roco protein family: a functional perspective. FASEB J. 22, 3103 3110.
152. Maroteaux L., Campanelli J. T. Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804 2815.
153. Martins L. M., Iaccarino I., Tenev T. et al. (2002) The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. 277, 439 444.
154. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265 1269.
155. Mata I. F., Wedemeyer W. J., Farrer M. J., Taylor J. P. Gallo K. A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286 293.
156. Meeus B., Nuytemans K., Crosiers D. et al. (2009) GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. Neurobiol. Aging doi :.
157. Melrose H., Lincoln S., Tyndall G., Dickson D. Farrer M. (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139, 791 794.
158. Melrose H. L., Kent C. B., Taylor J. P. et al. (2007) A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147, 1047 1058.
159. Menzies F. M., Yenisetti S. C. Min K. T. (2005) Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol. 15, 1578 1582.
160. Meulener M., Whitworth A. J., Armstrong-Gold C. E., Rizzu P., Heutink P., Wes P. D., Pallanck L. J. Bonini N. M. (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15, 1572 1577.
161. Miklossy J., Arai T., Guo J. P., Klegeris A., Yu S., McGeer E. G. McGeer P. L. (2006) LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 65, 953 963.
162. Miklossy J., Qing H., Guo J. P., Yu S., Wszolek Z. K., Calne D., McGeer E. G. McGeer P. L. (2007) Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol. 114, 243 254.
163. Miller D. W., Ahmad R., Hague S. et al. (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278, 36588 36595.
164. Mills R. D., Sim C. H., Mok S. S., Mulhern T. D., Culvenor J. G. Cheng H. C. (2008) Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1). J. Neurochem. 105, 18 33.
165. Mishizen-Eberz A. J., Norris E. H., Giasson B. I., Hodara R., Ischiropoulos H., Lee V. M., Trojanowski J. Q. Lynch D. R. (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 7818 7829.
166. Mizuno Y., Hattori N., Kubo S. I. et al. (2008) Progress in the pathogenesis and genetics of Parkinson's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 2215 2227.
167. Mizuta I., Satake W., Nakabayashi Y. et al. (2006) Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 15, 1151 1158.
168. Mochizuki H., Yasuda T. Mouradian M. M. (2008) Advances in gene therapy for movement disorders. Neurotherapeutics 5, 260 269.
169. Moore D. J., Zhang L., Dawson T. M. Dawson V. L. (2003) A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87, 1558 1567.
170. Moore D. J., West A. B., Dawson V. L. Dawson T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57 87.
171. Morgan N. V., Westaway S. K., Morton J. E. et al. (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38, 752 754.
172. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., Suda K. Mizuno Y. (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51, 890 892.
173. Mueller J. C., Fuchs J., Hofer A. et al. (2005) Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann. Neurol. 57, 535 541.
174. Muenter M. D., Forno L. S., Hornykiewicz O. et al. (1998) Hereditary form of parkinsonism - dementia. Ann. Neurol. 43, 768 781.
175. Muqit M. M., Abou-Sleiman P. M., Saurin A. T. et al. (2006) Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem. 98, 156 169.
176. Narendra D., Tanaka A., Suen D. F. Youle R. J. (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795 803.
177. Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843 9846.
178. Neumann M., Muller V., Gorner K., Kretzschmar H. A., Haass C. Kahle P. J. (2004) Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol. 107, 489 496.
179. Nichols W. C., Pankratz N., Hernandez D. et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410 412.
180. Nichols W. C., Kissell D. K., Pankratz N. et al. (2009) Variation in GIGYF2 is not associated with Parkinson disease. Neurology 72, 1886 1892.
181. Nieto M., Gil-Bea F. J., Dalfo E. et al. (2006) Increased sensitivitiy to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 27, 848 856.
182. Ning Y. P., Kanai K., Tomiyama H. et al. (2008) PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 70, 1491 1493.
183. Nishioka K., Hayashi S., Farrer M. J. et al. (2006) Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59, 298 309.
184. Obi T., Nishioka K., Ross O. A. et al. (2008) Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70, 238 241.
185. Olzmann J. A. Chin L. S. (2008) Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 4, 85 87.
186. Olzmann J. A., Bordelon J. R., Muly E. C., Rees H. D., Levey A. I., Li L. Chin L. S. (2007a) Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease. J. Comp. Neurol. 500, 585 599.
187. Olzmann J. A., Li L., Chudaev M. V., Chen J., Perez F. A., Palmiter R. D. Chin L. S. (2007b) Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J. Cell Biol. 178, 1025 1038.
188. Ozelius L. J., Senthil G., Saunders-Pullman R. et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424 425.
189. Paisan-Ruiz C., Jain S., Evans E. W. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595 600.
190. Paisan-Ruiz C., Bhatia K. P., Li A. et al. (2009) Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 65, 19 23.
191. Palacino J. J., Sagi D., Goldberg M. S., Krauss S., Motz C., Wacker M., Klose J. Shen J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614 18622.
192. Park J., Lee S. B., Lee S. et al. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157 1161.
193. Perez F. A. Palmiter R. D. (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl Acad. Sci. USA 102, 2174 2179.
194. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F. Zigmond M. J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090 3099.
195. Plun-Favreau H., Klupsch K., Moisoi N. et al. (2007) The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 9, 1243 1252.
196. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
197. Pramstaller P. P., Schlossmacher M. G., Jacques T. S. et al. (2005) Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. 58, 411 422.
198. Pridgeon J. W., Olzmann J. A., Chin L. S. Li L. (2007) PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5, e172.
199. Ramirez A., Heimbach A., Grundemann J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184 1191.
200. Ren Y., Zhao J. Feng J. (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 23, 3316 3324.
201. Rideout H. J., Larsen K. E., Sulzer D. Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899 908.
202. Ross O. A., Toft M., Whittle A. J. et al. (2006) Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388 393.
203. Ross O. A., Soto A. I., Vilarino-Guell C. et al. (2008a) Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 14, 539 543.
204. Ross O. A., Wu Y. R., Lee M. C. et al. (2008b) Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64, 88 92.
205. Saigoh K., Wang Y. L., Suh J. G. et al. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23, 47 51.
206. Sakaguchi-Nakashima A., Meir J. Y., Jin Y., Matsumoto K. Hisamoto N. (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 17, 592 598.
207. Samann J., Hegermann J., von Gromoff E., Baumeister R. Schmidt E. (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482 16491.
208. Santpere G. Ferrer I. (2009) LRRK2 and neurodegeneration. Acta Neuropathol. 117, 227 246.
209. Sato S., Chiba T., Nishiyama S. et al. (2006a) Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J. Neurosci. Res. 84, 1350 1357.
210. Sato S., Chiba T., Sakata E., Kato K., Mizuno Y., Hattori N. Tanaka K. (2006b) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J. 25, 211 221.
211. Schlossmacher M. G., Frosch M. P., Gai W. P. et al. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655 1667.
212. Shendelman S., Jonason A., Martinat C., Leete T. Abeliovich A. (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2, e362.
213. Shiba K., Arai T., Sato S., Kubo S. I., Ohba Y., Mizuno Y. Hattori N. (2009) Parkin stabilizes PINK1 through direct interaction. Biochem. Biophys. Res. Commun. 383, 331 335.
214. Shimura H., Hattori N., Kubo S. I. et al. (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668 672.
215. Shimura H., Hattori N., Kubo S. I. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302 305.
216. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. Selkoe D. J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263 269.
217. Shin N., Jeong H., Kwon J. et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314, 2055 2065.
218. Shojaee S., Sina F., Banihosseini S. S., Kazemi M. H., Kalhor R., Shahidi G. A., Fakhrai-Rad H., Ronaghi M. Elahi E. (2008) Genome-wide linkage analysis of a Parkinsonian-Pyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82, 1375 1384.
219. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E. M. Casari G. (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 3477 3492.
220. Sim C. H., Lio D. S., Mok S. S., Masters C. L., Hill A. F., Culvenor J. G. Cheng H. C. (2006) C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Genet. 15, 3251 3262.
221. Simon-Sanchez J. Singleton A. B. (2008) Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Genet. 17, 1988 1993.
222. Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
223. Smith W. W., Pei Z., Jiang H., Moore D. J., Liang Y., West A. B., Dawson V. L., Dawson T. M. Ross C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. USA 102, 18676 18681.
224. Smith W. W., Pei Z., Jiang H., Dawson V. L., Dawson T. M. Ross C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231 1233.
225. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
226. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313 319.
227. Springer W., Hoppe T., Schmidt E. Baumeister R. (2005) A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum. Mol. Genet. 14, 3407 3423.
228. Staropoli J. F., McDermott C., Martinat C., Schulman B., Demireva E. Abeliovich A. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37, 735 749.
229. Strauss K. M., Martins L. M., Plun-Favreau H. et al. (2005) Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14, 2099 2111.
230. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K. Takahashi R. (2001) A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 8, 613 621.
231. Tain L. S., Chowdhury R. B., Tao R. N., Plun-Favreau H., Moisoi N., Martins L. M., Downward J., Whitworth A. J. Tapon N. (2009) Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ. 16, 1118 1125.
232. Taira T., Saito Y., Niki T., Iguchi-Ariga S. M., Takahashi K. Ariga H. (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5, 213 218.
233. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., Tsuji S. Ikuta F. (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44, 437 441.
234. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S. M. Ariga H. (2001) DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 276, 37556 37563.
235. Tan E. K., Yew K., Chua E. et al. (2006) PINK1 mutations in sporadic early-onset Parkinson's disease. Mov. Disord. 21, 789 793.
236. Tan J. M., Wong E. S., Kirkpatrick D. S. et al. (2008) Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum. Mol. Genet. 17, 431 439.
237. Tanaka K., Suzuki T., Hattori N. Mizuno Y. (2004) Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695, 235 247.
238. Tang B., Xiong H., Sun P. et al. (2006) Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum. Mol. Genet. 15, 1816 1825.
239. Taymans J. M., Van den Haute C. Baekelandt V. (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 98, 951 961.
240. Thomas B. Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16, R183 R194.
241. Tomiyama H., Li Y., Funayama M. et al. (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov. Disord. 21, 1102 1108.
242. Tomiyama H., Li Y., Yoshino H., Mizuno Y., Kubo S. I., Toda T. Hattori N. (2009) Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism. Neurosci. Lett. 455, 159 161.
243. Ueda K., Fukushima H., Masliah E. et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282 11286.
244. Um J. W., Stichel-Gunkel C., Lubbert H., Lee G. Chung K. C. (2009) Molecular interaction between parkin and PINK1 in mammalian neuronal cells. Mol. Cell. Neurosci. 40, 421 432.
245. Unoki M. Nakamura Y. (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457 4465.
246. Valente E. M., Abou-Sleiman P. M., Caputo V. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158 1160.
247. Vasseur S., Afzal S., Tardivel-Lacombe J., Park D. S., Iovanna J. L. Mak T. W. (2009) DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl Acad. Sci. USA 106, 1111 1116.
248. Ved R., Saha S., Westlund B. et al. (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280, 42655 42668.
249. Vila M., Vukoasvic S., Jackson-Lewis V., Neystat M., Jakowec M. Przedborski S. (2000) J. Neurochem. 74, 721 729.
250. Volles M. J. Lansbury P. T. Jr. (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595 4602.
251. Von Coelln R., Thomas B., Savitt J. M., Lim K. L., Sasaki M., Hess E. J., Dawson V. L. Dawson T. M. (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl Acad. Sci. USA 101, 10744 10749.
252. van de Warrenburg B. P., Lammens M., Lucking C. B. et al. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56, 555 557.
253. West A. B., Moore D. J., Biskup S., Bugayenko A., Smith W. W., Ross C. A., Dawson V. L. Dawson T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842 16847.
254. West A. B., Moore D. J., Choi C. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223 232.
255. Whitworth A. J., Lee J. R., Ho V. M., Flick R., Chowdhury R. McQuibban G. A. (2008) Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis Model Mech 1, 168 174.
256. Wilkinson K. D., Lee K. M., Deshpande S., Duerksen-Hughes P., Boss J. M. Pohl J. (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670 673.
257. Xiong H., Wang D., Chen L. et al. (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J. Clin. Invest. 119, 650 660.
258. Yamada M., Mizuno Y. Mochizuki H. (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther. 16, 262 270.
259. Yamamura Y., Sobue I., Ando K., Iida M. Yanagi T. (1973) Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 23, 239 244.
260. Yang Y., Gehrke S., Haque M. E. et al. (2005) Inactivation of drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. USA 102, 13670 13675.
261. Yanping L., Wencheng L., Tinmarla F. O. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826 828.
262. Yao D., Gu Z., Nakamura T. et al. (2004) Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA 101, 10810 10814.
263. Yasuda T., Nihira T., Ren Y. R. et al. (2009) Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. J. Neurochem. 108, 932 944.
264. Yu W. H., Matsuoka Y., Sziraki I., Hashim A., Lafrancois J., Sershen H. Duff K. E. (2008) Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochem. Res. 33, 902 911.
265. Yun J., Cao J. H., Dodson M. W., Clark I. E., Kapahi P., Chowdhury R. B. Guo M. (2008) Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the pink1/parkin pathway in vivo. J. Neurosci. 28, 14500 14510.
266. Zadikoff C., Rogaeva E., Djarmati A., Sato C., Salehi-Rad S., St George-Hyslop P., Klein C. Lang A. E. (2006) Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson's disease patients. Mov. Disord. 21, 875 879.
267. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164 173.
268. Zhang Y., Gao J., Chung K. K., Huang H., Dawson V. L. Dawson T. M. (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97, 13354 13359.
269. Zhang N. Y., Tang Z. Liu C. W. (2008) Alpha-synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 283, 20288 20298.
270. Zhu X., Babar A., Siedlak S. L., Yang Q., Ito G., Iwatsubo T., Smith M. A., Perry G. Chen S. G. (2006) LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 1, 17.
271. Zimprich A., Biskup S., Leitner P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601 607.